REGENXBIO

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q4 2019 Results - Earnings Call Transcript

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Regenxbio (RGNX) Q4 Earnings Expected to Decline

Regenxbio: Fairly Valued Given The Current Risks But Could Have Eye-Watering Upside

Regenxbio: Revisiting This Gene Therapy 'Picks And Shovels' Play

Regenxbio: Amid Temporary Difficulty Is A Buying Opportunity

Regenxbio stock toppled below its 50-day moving average early Wednesday after the U.S. Food and Drug Administration put one of the biotech company's gene therapy candidates on hold.

This Biotech Dived After The FDA Put Its Gene Therapy Study On Pause

REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q3 2019 Results - Earnings Call Transcript

Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

CRISPR Therapeutics

Editas Medicine

Guardant Health Inc

Illumina

Intellia Therapeutics

Invitae

Veracyte

As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

8 Undervalued Biotech Stocks to Watch Now

Clearside Biomedical

ALPHARETTA, Ga., Oct.  30, 2019  (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that REGENXBIO Inc. (Nasdaq: RGNX) has exercised its option under the previously announced option and license agreement to license Clearside’s proprietary, in-office SCS Microinjector™ for the delivery of adeno-associated virus (AAV)-based therapeutics, including but not limited to RGX-314 delivery to the suprachoroidal space to potentially treat wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other conditions for which chronic anti-vascular endothelial growth factor (anti-VEGF) treatment is currently the standard of care.

Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector™ in AAV Gene Therapy Delivery

Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections

Denali Therapeutics

These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.

Big Pharma Has Mad Love For These 2 Biotechs

Adverum Biotechnologies

Kodiak Sciences Inc

Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.

3 Blindness-Fighting Biotech Stocks That Could Surge This Week

REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%

Amgen

Vertex Pharmaceuticals

Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.

Three Top Biotech Stocks, to Buy Right Now

President and CEO of Regenxbio Inc (30-Year Financial, Insider Trades) Kenneth T.

Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $563,250 of Shares

Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q2 2019 Results - Earnings Call Transcript

Regenxbio Inc (RGNX) President and CEO Kenneth T. Mills Sold $742,350 of Shares

Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?

As a leading gene therapy innovator, Regenxbio is undergoing many strong fundamental developments.

Regenxbio: More To Come After Zolgensma Approval

Regenxbio expects to obtain royalty payments from Novartis for Zolgensma after it was approved by the FDA to treat patients with spinal muscular atrophy.

With FDA Approval Of Zolgensma, Regenxbio Sets Out For First Revenue Stream

REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%

Novartis

A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.

Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio

Regenxbio, Inc. (RGNX) CEO Kenneth Mills on Q1 2019 Results - Earnings Call Transcript

As lucrative investments, gene therapy companies also are delivering hope for countless patients worldwide.

News for REGENXBIO Stock (RGNX)